Neurofeedback Effectiveness Trial in PTSD
Key facts
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Feb 2022
- Ended
- Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Neurofeedback
- Record updated
- 21 February 2022
- Why it stopped
- Due to challenges with the COVID-19 pandemic, our team has had to prioritize certain studies, which means we can no longer pursue this study at our site.
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- primary diagnosis of PTSD as determined by our pre-treatment assessment
- Due to online nature: must have access to (and ability to use) a computer/tablet with a working microphone and camera (or webcam) for assessments, and a tablet/smartphone for NFB, reliable access to a secure internet connection, and access to a quiet, private space for the assessments and sessions
- Ability to provide informed consent
- Fluency in written and spoken English
- must be resident of Ontario (due to restrictions of professional licenses)
Who cannot take part
- ECT (electroconvulsive therapy) within the last 12 months
- any implants, conditions, etc. that do not comply with 7T (Tesla) fMRI research safety standards (e.g., pacemaker, pregnancy/possible pregnancy)
- history of significant head injury/lengthy loss of consciousness (e.g., a Glasgow Coma Scale Score < 15 at the time of incident as assessed retrospectively by participant)
- significant untreated medical illness
- history of neurological or neurodevelopmental disorder
- history of any pervasive developmental disorder
- any medical disorder known to adversely affect cognition within the last 12 months
- lifetime bipolar or psychotic disorder
- significant dissociative disorder (as determined by our baseline assessment)
- alcohol/substance abuse or dependence within the last 3 months
- extensive narcotic use (e.g., fentanyl, oxycodone, etc.), use of anti-cholinergics, anti-psychotics, psychostimulants, or benzodiazepines
- suicide attempt in last 6 months
- pregnancy (due to impact of hormones on cognitive abilities)
- hearing or vision issues that would interfere with effective online participation:
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is an effectiveness trial investigating neurofeedback (NFB) in adults with PTSD (Post-Traumatic Stress Disorder). Participants will be randomly assigned to one of two treatment conditions - i) NFB, or ii) wait list. Due to the coronavirus pandemic, our study will, primarily, take place online (i.e., online assessment and treatment, with option of in-person fMRI, or functional magnetic resonance imaging, scans). NFB sessions will be conducted from home, with videoconferenced supervision by research staff. After study completion, individuals in the wait list condition will be offered the same NFB treatment.
The 2 groups in the trial
- Neurofeedback (NFB)Treatment being tested
Participants in the NFB condition will complete 19 weekly sessions of NFB from home with research staff supervision (via videoconferencing), and pre-, post- and 3-month follow-up assessments.
Treatment: Neurofeedback
- Wait ListNo study treatment, for comparison
Participants in the Wait List condition will receive no NFB for approximately 31 weeks, and will be asked to complete pre-, post- and 3-month follow-up assessments. After study completion, they will be offered the same 19 weeks of NFB.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Effectiveness Trial Examining Neurofeedback in Adults With PTSD
- Record updated
- 21 February 2022